Research Article

Chromosome 5p Region SNPs Are Associated with Risk of NSCLC among Women

Table 2

Associations between chromosome 5p SNPs and risk of NSCLC by race under a dominant model.

CaucasiansAfrican Americans
GeneSNP IdentifierMinor Allele Freq (%) ControlsHap Map CEU Allele FreqOR1
(95% CI)
Gene P-value2Minor Allele Freq (%) Controls3Hap Map ASW Allele FreqOR1
(95% CI)
Gene P-value2Comparison of Variant Allele Freq. P-value2

AHRRrs348470722912 bp of STP G/C0.37N/A0.93 (0.64–1.35)0.10N/A1.03 (0.43–2.47)<.0001
AHRRrs100783152 bp of STP T/G0.220.180.84 (0.58–1.22).220.260.230.65 (0.32–1.31).08.34
TERTrs2853690Ex16 + 203 G/A0.180.160.92 (0.62–1.36)0.340.290.81 (0.40–1.60)<.0001
TERTrs2075786IVS10 + 269 G/A0.330.401.17 (0.81–1.70)0.48N/A3.04 (1.267.30)<.0001
TERTrs2853677IVS2-4455 A/G0.440.421.76 (1.162.67)0.230.362.18 (1.084.38)<.0001
TERTrs27359402 A/G0.49N/A0.99 (0.66–1.49)0.55N/A0.38 (0.170.85).15
TERTrs1801075 T/C0.160.181.00 (0.68–1.49).060.160.121.12 (0.54–2.29).021.00
SLC6A3rs63472S405S0.250.251.10 (0.76–1.58)0.550.480.68 (0.30–1.56)<.0001
SLC6A3rs460700IVS4 + 2610 T/C0.230.300.79 (0.54–1.15)0.32N/A0.79 (0.40–1.57).01
SLC6A3rs26525112 G/A0.42N/A1.34 (0.90–2.00).170.65N/A0.92 (0.34–2.48).25<.0001
MTRRrs10380H622Y0.100.160.94 (0.59–1.49)0.330.281.06 (0.53–2.11)<.0001
MTRRrs1802059A664A0.390.310.88 (0.61–1.28)0.260.321.02 (0.52–2.02).002
MTRRrs9332Ex15-526 G/A0.110.191.01 (0.65–1.56)0.370.331.01 (0.50–2.03)<.0001
MTRRrs86592Ex15-405 A/T0.360.461.04 (0.72–1.51).810.51N/A0.90 (0.40–2.04).89.0001
AMACRrs2278008K277E0.260.201.14 (0.79–1.64)0.230.170.99 (0.48–2.05).36
AMACRrs840409IVS4 + 3803 G/C0.120.131.03 (0.66–1.59)0.10.040.59 (0.23–1.52).65
AMACRrs34677Q239H0.150.150.98 (0.66–1.48)0.11.050.88 (0.36–2.06).15
AMACRrs2287939S201L0.280.271.18 (0.82–1.70)0.160.200.67 (0.31–1.44).0009
AMACRrs109411122D175G0.480.441.20 (0.80–1.82)0.890.881.54 (0.18–13.08)<.0001
AMACRrs346892IVS1 + 169 A/C0.180.171.03 (0.70–1.52).630.500.470.58 (0.27–1.25).02<.0001
GHRrs2972395 C/T0.210.100.88 (0.60–1.28)0.22N/A1.00 (0.48–2.08).83
GHRrs2940930 G/A0.360.360.76 (0.52–1.11)0.140.161.72 (0.84–3.53)<.0001
GHRrs7732059 G/C0.22N/A1.29 (0.90–1.87)0.32N/A1.30 (0.65–2.59).01
GHRrs1858136IVS1 + 12052 G/C0.210.100.86 (0.59–1.26)0.26N/A0.69 (0.34–1.40).15
GHRrs29724182IVS1 + 59636 T/C0.480.501.12 (0.74–1.72)0.670.650.66 (0.23–1.91)<.0001
GHRrs2972419IVS1 + 59820 G/A0.210.150.93 (0.63–1.36)0.220.290.98 (0.47–2.02).87
GHRrs29409442IVS1 + 65085 A/C0.460.491.25 (0.83–1.89)0.580.561.14 (0.48–2.72).004
GHRrs29723922IVS1 − 70131 A/C0.41N/A1.30 (0.87–1.93)0.57N/A1.07 (0.46–2.52)<.0001
GHRrs33939197IVS1− 69908 T/C0.19N/A1.29 (0.88–1.87)0.16N/A0.86 (0.39–1.90).34
GHRrs29409132IVS1− 66349 G/T0.460.471.25 (0.83–1.89)0.67N/A0.60 (0.20–1.82)<.0001
GHRrs7735889IVS1− 3767 A/G0.250.341.10 (0.76–1.58)0.610.470.54 (0.23–1.30)<.0001
GHRrs7712701IVS2 + 4144 C/A0.23N/A1.20 (0.83–1.74)0.61N/A0.81 (0.33–2.00)<.0001
GHRrs28943882IVS2 + 29065 C/T0.170.211.16 (0.80–1.70)0.420.271.06 (0.52–2.15<.0001
GHRrs6873545IVS3 + 2059 T/C0.260.281.53 (1.052.21)0.450.581.12 (0.53–2.38)<.0001
GHRrs4451056IVS3 + 26148 G/C0.150.181.49 (1.012.20)0.18N/A0.69 (0.33–1.45).31
GHRrs6878512IVS3− 21121 C/T0.150.161.54 (1.042.27)0.23N/A0.68 (0.34–1.38).005
GHRrs68975302IVS3− 21055 T/C0.26N/A1.54 (1.062.23)0.54N/A0.97 (0.42–2.28)<.0001
GHRrs61792G186G0.260.291.46 (1.012.11)0.600.640.91 (0.33–2.48)<.0001
GHRrs29727802IVS8 + 1229 C/T0.250.261.50 (1.042.17)0.58N/A0.78 (0.30–2.00)<.0001
GHRrs6180Ex10 + 685 A/C0.470.450.73 (0.48–1.10).060.350.291.00 (0.49–2.03).03.003
SEPP1rs6413428Ex5 + 710 A/G0.230.261.56 (1.082.26)0.340.380.70 (0.34–1.42).002
SEPP1rs7579Ex5 + 626 C/T0.280.301.08 (0.75–1.55).060.160.170.78 (0.37–1.66).25.0009

1Adjusted for age at diagnosis/interview, smoking pack-year history, years of education, family history of lung cancer, history of COPD, adult aspirin use (never/ever), and BMI. 2Adjusted for multiple comparisons via the Benjamini and Hochberg False Discovery Rate (FDR) method. 3The minor allele differed for Caucasians and African Americans for the SNPs for which minor allele frequencies are bolded.